True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
South San Francisco, US
Size (employees)
12 (est)
True North Therapeutics was founded in 2013 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at True North Therapeutics

Nancy Stagliano

Nancy Stagliano


True North Therapeutics Office Locations

True North Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
951 Gateway Blvd
Show all (1)
Report incorrect company information

True North Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$164 m

Latest funding size

$45 m

Time since last funding

2 years ago


True North Therapeutics's latest funding round in October 2016 was reported to be $45 m. In total, True North Therapeutics has raised $164 m
Show all financial metrics
Report incorrect company information